What we're tracking right now.
Recent GLPZoom coverage: FDA decisions, recalls, GLP-1 shortage updates, legislation tracking, and editorial deep-dives.
Trackers
Recall & safety coverage
All recalls →Compounded semaglutide voluntary Class II recall, April 2026
Following FDA inspection findings of inconsistent dose-to-dose potency in compounded semaglutide vials, multiple 503A compounding pharmacies have issued voluntary Class II recalls covering specified lots. The FDA classifies this as Class II, meaning the products may cause temporary or medically reversible adverse health consequences (under- or over-dosing during titration). Patients currently using compounded semaglutide should check their vial labels against the affected lot lists published by their dispensing pharmacy and follow up with their prescriber to verify their current vial is unaffected or to arrange replacement.
FDA safety communication: tirzepatide and thyroid C-cell tumors
In February 2026 the FDA issued a safety communication reiterating the existing tirzepatide black-box warning regarding thyroid C-cell tumor risk based on rodent studies. The communication followed a small uptick in MedWatch reports of medullary thyroid carcinoma diagnoses in tirzepatide users; the FDA emphasized that causation has not been established (the underlying baseline rate of MTC in the general population is itself low, and confounding by patient history is significant). The agency confirmed that the tirzepatide prescribing information was not being updated and reaffirmed the existing contraindication in patients with personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN2).
Wegovy supply normalization (shortage status removed Q4 2025)
Following more than two years of intermittent Wegovy supply constraints, Novo Nordisk announced in November 2025 that all dose strengths of Wegovy are now available in sufficient supply to meet demand. The FDA subsequently removed all Wegovy dose strengths from the FDA Drug Shortage list. This normalization has narrowed the legal basis for compounding semaglutide — 503A compounding pharmacies historically relied on the FDA shortage list to justify compounded semaglutide production. As of 2026, telehealth services that previously offered compounded semaglutide have been transitioning patients to branded Wegovy or to alternative therapies.
Compounded tirzepatide voluntary recall, September 2025
Following FDA inspection findings, multiple 503A pharmacies voluntarily recalled compounded tirzepatide products distributed between April and August 2025. Findings included inconsistent active-ingredient concentration (potency variability between batches) and in two cases potential sterility concerns with reused syringes during compounding. No confirmed patient harm was reported, but affected patients were instructed to stop using identified lots and return them to the dispensing pharmacy. Many telehealth platforms which sourced compounded tirzepatide either transitioned patients to brand-name Zepbound or paused new compounded tirzepatide prescriptions.
FDA warning letters to 30+ compounding pharmacies, July 2025
Following the FDA's declaration that semaglutide and tirzepatide shortages were resolved (February and October 2025 respectively), the FDA issued warning letters to more than 30 compounding pharmacies that continued offering compounded versions of these molecules. The warnings cited failure to comply with 503A bulk-compounding rules, sourcing semaglutide salt forms from non-registered manufacturers, and making misleading claims about therapeutic equivalence to brand-name products. Many recipient pharmacies discontinued GLP-1 compounding within the 30-day response window; a small number challenged the FDA position legally and continue offering compounded GLP-1s in restricted circumstances.
FDA safety communication: Wegovy injection-site reactions
Based on a pattern of MedWatch reports, the FDA issued an updated safety communication reminding prescribers and patients of best practices to minimize injection-site reactions with Wegovy. Reports included localized erythema, induration, and lipohypertrophy at injection sites. The communication did not change the Wegovy label but reinforced manufacturer guidance: rotate injection sites between abdomen, thigh, and upper arm; avoid same exact location consecutive weeks; use room-temperature pens (refrigerated pens increase injection-site reactions); and monitor for signs of localized infection requiring medical evaluation.
Latest articles
All articles →- glp1
Wegovy prior authorization: the step-by-step approval playbook (2026)
Wegovy denials usually come from incomplete documentation, not clinical ineligibility. Here's the exact step-by-step process that gets approval on the first submission, plus what to do when denied.
- glp1
GLP-1 hair loss timeline: when it starts, peaks, and recovers (2026)
Hair shedding on Wegovy, Ozempic, or Zepbound follows a predictable pattern tied to rapid weight loss, not the drug itself. Here's the week-by-week timeline, why it happens, and what actually shortens recovery.
- glp1
Wegovy vs Ozempic in 2026: same drug, different prescribing rules
Wegovy and Ozempic are both semaglutide. Wegovy is FDA-approved for weight management; Ozempic for type 2 diabetes. Same active ingredient — but different dose, different insurance pathway, different cost, and different clinical conversation. Here's the full comparison.
- glp1
Mounjaro vs Zepbound (2026): tirzepatide split by indication
Mounjaro and Zepbound are both tirzepatide — Eli Lilly's dual GLP-1/GIP agonist. Mounjaro is FDA-approved for type 2 diabetes; Zepbound for chronic weight management and obstructive sleep apnea in adults with obesity. Here's the regulatory split, dose ladder, insurance reality, and how to switch.
- glp1
Wegovy cost without insurance in 2026: cheapest legitimate paths
Wegovy's pharmacy list price is ~$1,349 per month. For uninsured patients, the cheapest legitimate paths in 2026 are NovoCare self-pay at $499/month, transitioning to oral orforglipron at $149/month when prescriber agrees, or compounded semaglutide (a narrowing legal grey zone). Here are the actual options and what's changing.
- glp1
Wegovy weight loss timeline: week-by-week expectations (2026)
Wegovy doesn't drop the scale immediately. Most patients lose 1-2 pounds in weeks 1-4, hit a 5% loss around month 4, reach 10% by month 8, and approach 15% by week 68. Here's what to actually expect, what's normal during titration, and when to call your prescriber if results lag.
- glp1
Ozempic injection sites and technique: complete how-to (2026)
Ozempic is injected once weekly under the skin (subcutaneous) of your abdomen, thigh, or upper arm. Site rotation matters — repeated injection in one spot causes lipohypertrophy that reduces drug absorption. Here's the full technique, site rotation schedule, what to avoid, and how to troubleshoot common problems.
- glp1
Foods to avoid on GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) in 2026
GLP-1 medications slow gastric emptying — foods that already sit heavy in the stomach (fried, high-fat, fibrous) become much worse. Sulfur-rich foods (eggs, alliums, cruciferous) trigger sulfur burps. Alcohol, carbonated drinks, and spicy foods worsen nausea. Here's the complete avoidance + substitution guide.
- glp1
GLP-1 medications and alcohol in 2026: what to know
GLP-1 medications (Wegovy, Ozempic, Zepbound, Mounjaro) are not FDA-contraindicated with alcohol, but most patients find alcohol tolerance significantly reduced. Slowed gastric emptying means the same drink hits harder and later. Many patients lose interest in alcohol entirely. Here's the science, the practical limits, and the situations to avoid.
- glp1
Wegovy vs Ozempic side effects in 2026: complete comparison
Wegovy and Ozempic are both semaglutide so the side-effect profile is nearly identical: nausea, constipation, diarrhea, vomiting, fatigue. Differences exist primarily because Wegovy goes to a higher max dose (2.4mg vs 2.0mg), which means slightly more frequent and severe GI side effects. Here's the head-to-head data, what to expect, and how to manage.
- glp1
Does BCBS cover Wegovy in 2026? Blue Cross coverage by plan type
Blue Cross Blue Shield coverage of Wegovy varies dramatically by state, employer plan, and member type. Federal BCBS (FEP) covers Wegovy. Many commercial BCBS plans require prior authorization with BMI ≥30 + comorbidity. Some plans exclude obesity medications entirely. Here's how to check your specific BCBS plan + what to do if denied.
- glp1
GLP-1 muscle loss in 2026: how much, and how to prevent it
Weight loss from any source includes some muscle loss. On GLP-1 medications, roughly 25-40% of the weight lost is typically lean mass — meaning if you lose 40 pounds total, 10-16 of those pounds are muscle. This matters because lean mass drives metabolism, function, and long-term maintenance. Here's how to lose mostly fat instead.
Press inquiries: [email protected] · Press kit · RSS feed